Dr. Patrick Y. Lu is the founder and has led Sirnaomics from an early discovery effort to an siRNA therapeutics product company, with multiple programs currently at clinical stage. Dr. Lu brings 25+ years of nucleic acid drug development experience in Novartis, Digene and Intradigm which he was co-founder. He has led raising over $270 million for the company up to now and developing novel siRNA therapeutic, STP705, for treatment of cancer and fibrosis diseases.

Dr. Michael V. Molyneaux has unique experience of over 20 years in diversified clinical environments and industry, with proven results in clinical operations. Dr. Molyneaux is a board certified Medical Doctor and has completed his MBA. He was previously the CMO of Macrocure Inc. Dr. Molyneaux’s role is to help define therapeutic programs that will match the key properties of our lead product candidates. He is responsible for the development of clinical operations, medical affairs and regulatory affairs.

Dr. David Mark Evans has over 25 years of pharmaceutical drug discovery experience, primarily in oncology. Dr. Evans has worked in the RNAi field since 2003, holding senior management positions at Translational Genomics Research Institute (TGEN) and Dharmacon, Inc. (ThermoFisher Scientific, Inc.) prior to joining our company. He also previously held positions at Serono Pharmaceuticals and Millennium Pharmaceuticals, Inc. He is responsible for scientific, technological and research operations in oncology and fibrosis.

Dr. Zhifeng Long has 33+ years industrial experience, including 30 years in directing translational research, drug development, pharmacotox studies, clinical research, molecular diagnostic assays, drug manufacturing, quality control and quality assurance. Prior to joining our Group, Dr. Long served as the president and chief executive officer in Personal Diagnostix, Inc. from May 2010 to June 2018. In his current role, he is responsible for delivery platform research and development and optimization, formulation development, analytical sciences as well as quality control and assurance.

Dr. Samarsky has been at the inception of RNAi technology since 2001 and has been supervising technology innovation and drug discovery teams in multiple international companies. He served as VP of Technology Development at RXi Pharmaceuticals, USA (2007), SVP of Technology and International Business Development at RiboBio, China (2011) and Chief Scientific Officer at Silence Therapeutics, Germany (2016). He has authored more than 40 scientific papers, articles, book chapters, patents, and patent applications, and has been an invited speaker at more than 100 international conferences.

Dr. Edward Yongxiang Wang has 25+ years of research experience and has in-depth knowledge of biopharmaceutical research and the IND and NDA processes. Prior to joining our Group, Dr. Wang served as the deputy general manager at Shanghai Furen Medicine R&D Co., Ltd. from October 2016 to June 2018 and the director of vaccine production in Newlink Genetics Inc., for a special project to fight the Ebola Epidemic from August 2014 to June 2016. In our Group, he leads our teams focused on manufacturing and regulatory compliance.

Dr. Welch has over 27 years of experience in Pharmaceutical and Biotechnology focusing on Drug Substance and Drug Product development and manufacturing. Dr. Welch has held leadership positions in both large and small companies including Emergent BioSolutions where he held roles as Vice President of Development Services and DVS site head within the CDMO business unit as well as Vice President for Process and Analytical Development in the Vaccines and the BioDefense divisions.  He has also held leadership positions at Lonza Microbial US and Cambrex BioScience, Baltimore.

John Xu, MD, graduated from Suzhou Medical College (1982) and Shanghai Second Medical University (1987), was Forgarty fellow in NIH (NHGRI, 1994), worked in the industry from 1999 at Novartis, Enzon, etc. and joined Sirnaomics in 2008 as Vice President in charge of company’s pre-clinical studies.  John also serves now as General Manage of Sirnaomics Suzhou, one of Sirnaomics subsidiaries in China.

Mr. Wing Kei Yip has 12+ years of transaction experiences in merger & acquisitions, initial public offerings, and private equity. Prior to joining Sirnaomics, Mr. Yip worked in Credit Suisse (Hong Kong) Limited from 2015 to 2018 and successively served as an associate in Investment Banking Division and a vice president in Ultra High Net Worth Entrepreneur Coverage Department.In his current role, he manages the overall fundraising process of the group and communication with the banking and investor communities.

Ms. Yun Zhang joined our Group in 2015 and was responsible for the operation and management of Guangzhou Sirnaomics, has been serving as the board secretary of our Group since 2018 and was appointed as the chief operating officer of Greater China in November 2020. Prior to joining our Group, Ms. Zhang worked at the National Foundation for Cancer Research in Maryland, the U.S. from 2009 to 2015, with her last position serving as a program manager. She serves as a director and the vice president of marketing and communication of the Chinese Biopharmaceutical Association since 2013. In her current role, she is responsible for financing, listing execution, investor relations and operation management affairs of Greater China of our Group.

George has 30+ years of industrial business development and corporate management experience at multiple international firms, including GE, ASME, CHRG and Quantum Communications. Prior to joining Sirnaomics, George served as a managing director of a US listed bio-pharmaceutical company, responsible for its corporate affairs and US operations. In his current role, George manages general operations of the company, including corporate development, finance and accounting, human resources and general administration.

John has 25+ years of human resource (HR) management experience focused within the biopharmaceutical industry. He is currently responsible for all HR functions within the Company which includes talent acquisition, performance management, benefits, compensation and payroll, and has a lead role in corporate risk management. In his past leadership roles, John built and oversaw the HR functions for several high growth or emerging biopharmaceutical companies including two public companies (Guilford Pharmaceuticals and PharmAthene).